Table 1.
Host | Study group | Enriched bacteria | Reference |
Oral microbiota | |||
Human | Prediagnostic samples, PDAC versus matched controls | Porphyromonas gingivalis, Aggregatibacter actinomycetemcomitans | Fan et al 20 |
Human | PDAC versus healthy controls | Neisseria elongate, Streptococcus mitis | Farrell et al 21 |
Gut microbiota | |||
Human | PDAC versus healthy controls | Prevotella, Veillonella, Klebsiella, Selenomonas, Hallella, Enterobacter, Cronobacter | Ren et al 18 |
Human | PDAC versus healthy controls | Bacteroidetes, Veillonellaceae, Akkermansia, Odoribacter | Half et al 22 |
Human | PDAC versus healthy controls | Proteobacteria, Synergistetes, Euryarchaeota | Pushalkar et al 23 |
Mouse | PDAC spontaneous model | Actinobacteria, Deferribacteres, Bifidobacterium pseudolongum | |
Mouse | PDAC subcutaneous model | Bacteroidetes, Firmicutes | Sethi et al 48 |
Mouse | PDAC spontaneous model | Bacteroides, Alphaproteobacteria | Mendez et al 26 |
Tumour microbiota | |||
Human | PDAC versus healthy controls | Gammaproteobacteria | Geller et al 37 |
Human | PDAC tumour versus gut | Proteobacteria (Pseudomonas, Elizabethkingia) | Pushalkar et al 23 |
Human | PDAC | Acinetobacter, Afipia, Corynebacterium, Escherichia, Propionibacterium | Thomas et al 27 |
Human | PDAC | Gammaproteobacteria, Bacilli, Actinobacteria | Riquelme et al 40 |
Human | PDAC long-term survivors versus short-term survivors | Pseudoxanthomonas, Streptomyces, Saccharopolyspora, Bacillus clausii | |
Cyst microbiota | |||
Human | IPMN, MCN, SCA, pseudocysts | Bacteroides, Escherichia/Shigella, Fusobacterium, Acidaminococcus, Sphingomonas, Bifidobacterium | Li et al 35 |
Human | Cancerous versus non-cancerous PCNs | Fusobacterium nucleatum, Granulicatella adiacens | Gaiser et al 36 |
IPMN, intraductal papillary mucinous neoplasm; MCN, mucinous cystic neoplasm; PCN, pancreatic cystic neoplasias; PDAC, pancreatic ductal adenocarcinoma; SCA, serous cystadenoma.